Vaxcyte, Inc.
Vaxcyte, Inc. (Nasdaq: PCVX) is a clinical-stage vaccine company developing vaccines against bacterial diseases using its XpressCF cell-free protein synthesis platform. Its pipeline is led by pneumococcal conjugate vaccine candidates VAX-31, VAX-24 and VAX-XL, designed for adult and pediatric use to cover a broad… From the company’s description.
In fiscal 2025, Vaxcyte, Inc. reported a net loss of $766.63M. Operations used $655.58M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vaxcyte, Inc. does
In the company’s own words
Vaxcyte, Inc. (Nasdaq: PCVX) is a clinical-stage vaccine company developing vaccines against bacterial diseases using its XpressCF cell-free protein synthesis platform. Its pipeline is led by pneumococcal conjugate vaccine candidates VAX-31, VAX-24 and VAX-XL, designed for adult and pediatric use to cover a broad range of pneumococcal strains. The company is also developing VAX-A1 for Group A Streptococcus and has paused development of its preclinical Shigella candidate, VAX-GI, beyond the preclinical stage. Vaxcyte uses cell-free production and site-specific conjugation to develop conjugate and protein vaccine candidates; it has no products approved for commercial sale. Its principal programs target pneumococcal disease, including invasive disease and pneumonia, while VAX-A1 addresses a disease with no currently approved vaccine. Vaxcyte operates as a single vaccine-development business, with no reportable segments described. Its XpressCF platform is also used for discovery-stage programs. The company reports no product revenue and had 2025 research and development expenses of $[not stated in provided text]. Its website is https://vaxcyte.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN CARLOS, CA
- Fiscal year end
- December
- CIK
- 1649094
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vaxcyte, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vaxcyte, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vaxcyte, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vaxcyte, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vaxcyte, Inc.'s last four quarterly filings that the numbers alone won't show?”